Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Go back to Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting| (NASDAQ: TSHA) | Delayed: 6.53 +0.11 (1.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.42 | 52 Week High | $ | |||
| Open | $6.50 | 52 Week Low | $ | |||
| Day High | $6.70 | P/E | N/A | |||
| Day Low | $6.47 | EPS | $ | |||
| Volume | 3,035,825 | |||||
